Every GLP-1 clinic learns the same lesson eventually: prescribing Wegovy is the easy part. Getting a patient from the starting dose to the maintenance dose, five months later, without them dropping off at the first bad week, is where the operation either holds together or doesn't. The clinical schedule is fixed. Everything around it is a service design problem.
The licensed dose ladder, strength by strength
Wegovy's dose escalation schedule is set out in the product licence, not something a clinic or prescriber can shortcut for convenience. It moves through five pen strengths, and the standard pattern is a step up roughly every four weeks, giving the body time to adjust before the next increase.
The usual sequence runs: 0.25mg for the first four weeks (a starting dose, not a treatment dose), then 0.5mg, then 1mg, then 1.7mg, each held for around four weeks, before reaching the 2.4mg maintenance dose that most patients stay on long term. Prescriber discretion applies throughout: a prescriber can hold a patient at a lower step for longer if tolerance is a problem, but can't skip a step to speed things up.
Why titration is an operational problem, not just a clinical one
The prescribing decision happens once, at the start. The operational work happens five or six times over the following months: confirming the patient is ready to step up, getting the right strength dispensed and delivered on time, and catching the people who go quiet after a rough week rather than finding out when they cancel.
Clinics that treat titration as a one-off prescription rather than a pathway tend to see the same pattern: strong adherence on the starting dose, then a steady drift in attendance as the dose, and the side effects, climb. That drift is rarely about the medicine failing. It's usually a support gap at the exact moment a patient needed a check-in and didn't get one.
Building a check-in at every step
A workable pathway puts a structured touchpoint before every dose increase, not just at the three-month review most clinics default to. It doesn't need to be a full consultation each time; a short structured check-in, by message, call or app form, covers most of what a prescriber needs to confirm before authorising the next strength.
- Tolerability since the last increase (GI symptoms, injection-site reaction, appetite change)
- Whether any symptom is severe enough to need prescriber review before stepping up
- Adherence: injections taken on schedule, any missed doses
- Weight and wellbeing trend, used supportively rather than as the only metric that matters
- Whether the patient feels ready for the next strength, or wants to hold
Where a check-in flags a problem, the record needs to route straight to the prescriber rather than sitting in a general queue. The whole point of the pathway is catching the hesitation before it becomes a silent drop-off.
The dose ladder itself is fixed by the licence. What a clinic controls, and what actually determines whether patients finish the course, is the check-in at every step, stock continuity across five pen strengths, and a prescriber who can slow the pace down when tolerance says so.
Five SKUs, one forecast: the stock-planning side
Running a titration pathway properly means holding stock across five separate pen strengths at once, not one SKU with five labels. Patients move through the ladder at different speeds, some held longer on a step by the prescriber, which spreads demand unevenly across strengths rather than funnelling it into whichever one is newest.
Get the forecast wrong and the failure shows up as either expired stock on the early strengths, because fewer patients than planned needed a slow start, or a gap on the maintenance strength just as the largest cohort reaches it. Cold-chain handling adds another layer: every strength needs the same temperature discipline from warehouse to doorstep, and a short-dated batch on a slow-moving strength is a real wastage risk, not a theoretical one.
When the schedule needs to slow down
Not every patient tolerates the standard four-week steps. Where GI side effects are significant, a prescriber may choose to hold a patient on their current strength for an extra cycle rather than pushing on to the next one, and that decision sits with the prescriber alone, never with an operations team trying to keep a batch schedule tidy.
This is where the dispensing side of GLP-1 supply has to stay flexible rather than treating the titration schedule as fixed logistics. A system built around a rigid four-week cadence will keep nudging patients to step up on time even when the clinical note says otherwise, which is exactly the kind of mismatch that erodes trust in the pathway.
The dose ladder isn't the hard part. Keeping the same patient engaged for five months while the dose, and the side effects, keep changing under them is.
The referral line: what goes straight to the prescriber
Most issues on the dose ladder are manageable with reassurance, hydration advice or a longer hold at the current strength. A smaller set of symptoms need the prescriber immediately, and a titration pathway only works if the people running the check-ins know exactly where that line sits.
- Severe, persistent abdominal pain, which can signal pancreatitis
- Signs of gallbladder problems, such as right-upper-abdominal pain with fever or jaundice
- Vomiting or diarrhoea severe enough to risk dehydration
- Any sudden change in mood or new thoughts of self-harm
- Significant vision changes in a patient with diabetes
Any suspected adverse reaction that's serious or unexpected should also be considered for a Yellow Card report to the MHRA, which is a standing obligation on the prescribing service, not an optional extra once titration is underway.
Where PExpo fits
PExpo's dispensing layer is built around exactly this kind of multi-strength, multi-month pathway: holding stock across all five Wegovy strengths under the same cold-chain discipline, dispensing against the dose a prescriber has actually authorised rather than a default schedule, and surfacing a missed check-in or a flagged symptom to the clinical team the same day rather than at the next batch run.
For a clinic running or launching a GLP-1 service, that means the titration pathway can scale past a handful of patients without the stock forecasting and escalation routing becoming a manual, error-prone job for someone on the clinical team.
Wegovy's titration schedule reads simply on paper: five strengths, four-week steps, one maintenance dose. Running it well for a real caseload is a different job, built from check-ins, stock forecasting across strengths, and a clear referral line, not just a prescription. Clinics weighing up whether to build that operational layer themselves or partner for it should look at the cost of running it in-house before committing either way.
Frequently asked questions
What doses does Wegovy come in?
Wegovy comes in five pen strengths: 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg. Patients start on the lowest strength and step up roughly every four weeks under the product licence, reaching 2.4mg as the usual long-term maintenance dose. Prescriber discretion applies to the exact pace for any individual patient.
Can a patient skip a dose step to reach maintenance faster?
No. The step-up schedule is set by the product licence and exists to let the body adjust before the next increase. A prescriber can hold a patient at a lower strength for longer if tolerance is a problem, but moving up early isn't something a clinic or patient can choose on their own.
What happens if a patient misses doses for several weeks?
A meaningful gap in dosing usually needs a prescriber review before restarting rather than simply resuming at the last strength. Many prescribers will restart at a lower dose and re-titrate, since tolerance built up earlier in the schedule isn't guaranteed to have held. This is a clinical decision, not an operational one.
